Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMA

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

Market access opportunities in China

Pope Woodhead highlights the key steps to accessing the high-value therapeutics market in China

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

Novartis building

NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

But draft guidance doesn't recommend Forest’s Colobreathe

Roche - Basel

EMA launches probe into Roche’s adverse event reporting

Pharma company allegedly failed to follow pharmacovigilance procedures

- PMLiVE

Abbott and Seattle expand antibody-drug conjugate collaboration

Pharma company could pay $220m per oncology target

Eisai’s epilepsy drug Fycompa gets green light in US

Japanese firm predicts global sales of more than $1bn at peak

- PMLiVE

Vivus fails to get European backing for obesity treatment Qsiva

EMA raises concerns about drug’s cardiovascular safety

- PMLiVE

GE Healthcare launches Spotify-powered breast cancer initiative

Give A Little Beat jukebox aims to connect people through music

- PMLiVE

Ireland forges drug pricing pact with pharma

Could cut drug bill by €400m

- PMLiVE

FDA panel backs Sanofi’s Kynamro for high cholesterol

Recommendation comes despite safety concerns

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links